Rep. Richard McCormick Unloads Johnson & Johnson (NYSE:JNJ) Stock

Key Points

• Rep. Richard McCormick sold $1,001–$15,000 of Johnson & Johnson stock on July 30, 2026, from his Growth Partners Roth IRA. He also sold similarly sized positions in 10 other companies, including Medtronic, PepsiCo, Home Depot and McDonald’s.
• Johnson & Johnson reported quarterly EPS of $2.90, exceeding estimates of $2.84, while revenue rose 6.6% year over year to $25.31 billion. The company reaffirmed 2026 EPS guidance of $11.60–$11.75.
• JNJ announced a quarterly dividend of $1.34 per share, equivalent to a $5.36 annualized payout and a 2.0% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $268.22.

Representative Richard McCormick (Republican-Georgia) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on August 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on July 30th. The trade occurred in the Representative's "GROWTH PARTNERS ROTH IRA" account.

Representative Richard McCormick also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Medtronic NYSE: MDT on 7/30/2026.
• Sold $1,001 - $15,000 in shares of NextEra Energy NYSE: NEE on 7/30/2026.
• Sold $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/30/2026.
• Sold $1,001 - $15,000 in shares of McDonald's NYSE: MCD on 7/30/2026.
• Sold $1,001 - $15,000 in shares of L3Harris Technologies NYSE: LHX on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Intercontinental Exchange NYSE: ICE on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Illinois Tool Works NYSE: ITW on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Home Depot NYSE: HD on 7/30/2026.
• Sold $1,001 - $15,000 in shares of Emerson Electric NYSE: EMR on 7/30/2026.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $262.43 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The stock has a fifty day simple moving average of $252.52 and a two-hundred day simple moving average of $241.60. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $274.90. The firm has a market cap of $632.43 billion, a price-to-earnings ratio of 30.41, a price-to-earnings-growth ratio of 2.48 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business's revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is 62.11%.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,972 shares of company stock valued at $12,295,205 over the last three months. Corporate insiders own 0.16% of the company's stock.

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently added to or reduced their stakes in JNJ. Brighton Jones LLC lifted its holdings in shares of Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. United Bank increased its holdings in Johnson & Johnson by 110.7% during the first quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after buying an additional 4,876 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock worth $896,000 after purchasing an additional 692 shares during the period. Wealth Group Ltd. increased its holdings in Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after acquiring an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. raised its stake in Johnson & Johnson by 9.8% during the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after acquiring an additional 6,584 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on JNJ shares. HSBC set a $290.00 price target on Johnson & Johnson and gave the stock a "buy" rating in a report on Monday, July 6th. Royal Bank Of Canada increased their target price on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. TD Cowen lifted their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. The Goldman Sachs Group reiterated a "buy" rating and issued a $282.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research note on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $268.22.

About Representative McCormick

Rich McCormick (Republican Party) is a member of the U.S. House, representing Georgia's 7th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. McCormick (Republican Party) is running for re-election to the U.S. House to represent Georgia's 7th Congressional District. He declared candidacy for the 2026 election. Rich McCormick lives in Suwanee, Georgia. McCormick served in the U.S. Marine Corps and the U.S. Navy. He earned an M.B.A. from National University and an M.D. from Morehouse School of Medicine. McCormick's career experience includes working as an emergency medicine physician with Gwinnett Medical Center and Northside Hospital, a Marine officer instructor with Georgia Tech and Morehouse College, and a pilot.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source